DrugPatentWatch Database Preview
NUVARING Drug Profile
Email this page to a colleague
» See Plans and PricingWhen do Nuvaring patents expire, and what generic alternatives are available?
Nuvaring is a drug marketed by Organon Sub Merck and is included in one NDA.
The generic ingredient in NUVARING is ethinyl estradiol; etonogestrel. There are twenty-six drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; etonogestrel profile page.
Summary for NUVARING
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 3 |
| Bulk Api Vendors: | 1 |
| Clinical Trials: | 26 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NUVARING |
| Drug Sales Revenues: | Drug sales revenues for NUVARING |
| DailyMed Link: | NUVARING at DailyMed |
Recent Clinical Trials for NUVARING
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Andrea Roe, MD, MPH | Phase 4 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 4 |
| University of Washington | Phase 4 |
Pharmacology for NUVARING
| Drug Class | Progestin Estrogen |
| Mechanism of Action | Estrogen Receptor Agonists |
Paragraph IV (Patent) Challenges for NUVARING
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| NUVARING | RING;VAGINAL | ethinyl estradiol; etonogestrel | 021187 | 2013-06-17 |
US Patents and Regulatory Information for NUVARING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Organon Sub Merck | NUVARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 021187-001 | Oct 3, 2001 | AB | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for NUVARING
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Organon Sub Merck | NUVARING | ethinyl estradiol; etonogestrel | RING;VAGINAL | 021187-001 | Oct 3, 2001 | Start Trial | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for NUVARING
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 123813 | Start Trial |
| China | 1163222 | Start Trial |
| Russian Federation | 2206325 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NUVARING
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1453521 | 93156 | Luxembourg | Start Trial | PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211 |
| 1214076 | C01214076/01 | Switzerland | Start Trial | PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008 |
| 0398460 | C300221 | Netherlands | Start Trial | PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
